Phase II Simulation

mRNA Cancer Vaccine Mechanism & Trial Simulator

mRNA-LNP / DC
CD8+ Primed T-Cell
Malignant Cell
MHC-I Presentation Efficiency
91.4%
Affinity <100nM IC50
CD8+ Clones Primed
3
Polyclonal Expansion
Tumor Lysis Rate
88.2%
Cytotoxic Clearance
RFS Hazard Ratio (vs SOC)
0.56
44% Risk Reduction
Exhaustion Mitigation
0.94
PD-1 / PD-L1 Blocked
Enjoy this tool? Build your own with Super